1. Home
  2. OUST vs EVO Comparison

OUST vs EVO Comparison

Compare OUST & EVO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Ouster Inc.

OUST

Ouster Inc.

HOLD

Current Price

$24.98

Market Cap

1.3B

Sector

Technology

ML Signal

HOLD

Logo Evotec SE

EVO

Evotec SE

HOLD

Current Price

$3.61

Market Cap

1.1B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
OUST
EVO
Founded
2015
1993
Country
United States
Germany
Employees
N/A
N/A
Industry
Industrial Machinery/Components
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.3B
1.1B
IPO Year
N/A
2021

Fundamental Metrics

Financial Performance
Metric
OUST
EVO
Price
$24.98
$3.61
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
5
1
Target Price
$34.80
$7.00
AVG Volume (30 Days)
1.9M
66.9K
Earning Date
11-04-2025
11-05-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$137,298,000.00
$887,396,457.00
Revenue This Year
$35.72
N/A
Revenue Next Year
$35.65
$8.52
P/E Ratio
N/A
N/A
Revenue Growth
30.20
N/A
52 Week Low
$6.34
$2.84
52 Week High
$41.65
$4.80

Technical Indicators

Market Signals
Indicator
OUST
EVO
Relative Strength Index (RSI) 48.27 58.06
Support Level $23.53 $3.39
Resistance Level $28.08 $3.63
Average True Range (ATR) 1.95 0.09
MACD -0.05 -0.00
Stochastic Oscillator 17.92 66.23

Price Performance

Historical Comparison
OUST
EVO

About OUST Ouster Inc.

Ouster Inc is a provider of lidar sensors for the automotive, industrial, robotics, and smart infrastructure industries. Ouster's products include high-resolution scanning and solid-state digital lidar sensors, Velodyne Lidar sensors, and software solutions. The company operates in the Americas, Asia and Pacific, Europe, Middle East, and Africa regions. It derives maximum revenue from Americas.

About EVO Evotec SE

Evotec is a drug discovery partnership firm providing solutions to pharmaceutical and biotechnology companies, academic institutions, foundations, and nonprofit organizations. The company offers services in a variety of therapeutic areas, including central nervous system disorders, diabetes, inflammation, oncology, infectious diseases, and women's health. The shared R&D segment, roughly 80% of sales, provides drug discovery and manufacturing services on a typical fee-for-service basis and integrated drug discovery collaborations based on its proprietary, internally developed assets. The Just-Evotec Biologics segment, about 20% of sales, offers CDMO services for biologics. As of 2023, the company has over 5,000 employees and 18 production sites mainly in Europe and the United States.

Share on Social Networks: